However, in a pragmatic approach, combination of Ki67 hotspot score as categorical variable and tumor grade may identify approximately 40% of patients who do not need OncotypeDx and safely skip chemotherapy—since only about 8% of them would miss out potential benefits from chemotherapy. This evidence concerns the gene MKI67 and neoplasm.